An Open, Randomized,Positive Control, Multicenter Phase III Clinical Study of SHR A1904 for Injection Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patients With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 24 Oct 2024
At a glance
- Drugs SHR-A1904 (Primary) ; Docetaxel; Irinotecan; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Hengrui Pharmaceutical
- 24 Oct 2024 New trial record